After four years of following patients taking Wegovy, the trial revealed how quickly it worked, if patients kept the weight off -- and something else surprising.
Researchers at the European Congress of Obesity released results of a new clinical trial of Wegovy, the weight loss version of Ozempic .drugs can help with heart failure and heart attack. This week at the European Congress of Obesity, researchers released the overall results of the longest clinical trial yet of the drug Wegovy, the weight loss version of Ozempic .
"These medications may have an effect on inflammation, and chronic inflammation can contribute to a lot of health issues," he said. But for shedding pounds, the results show the average body weight reduction of about 10% continued for a year and was more or less sustained for up to four years. As far as safety, there are no surprises. Serious side effects such as gastroparesis were rare. The more common nausea, diarrhea and constipation were reasons why some people stopped taking it. The steep out-of-pocket costs even with insurance are another reason.Ali said people should remember that Wegovy and other similar weight loss drugs are not magic potions - you still have to do the work.
Weight Loss Ozempic Clinical Trial Study Side Effects 14816519
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy users keep weight off for 4 years: How Wegovy helps the heartPatients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug.
Read more »
Healthy Returns: U.S. drug shortages reach record high, hitting Wegovy, ADHD medicationsU.S. medication shortages are at a record high so far this year. Meanwhile, UnitedHealth revealed the financial impact of the Change Healthcare cyberattack.
Read more »
3.6 million Medicare enrollees may now be eligible for Wegovy coverageAbout 3.6 million Medicare enrollees may qualify for coverage of the anti-obesity drug Wegovy.
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyUS Senate committee investigates pricing of Novo's Ozempic and Wegovy
Read more »
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyA U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
Read more »